{"disease":{"id":"refractory-status-epilepticus","name":"refractory status epilepticus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07383779","title":"Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":466,"lead_sponsor_name":"Versailles Hospital","has_results":false},{"nct_id":"NCT07281027","title":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":438,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT04333082","title":"Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction","phase":"","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT07496749","title":"KD Treatment for Super-refractory Status Epilepticus","phase":"NA","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05830864","title":"Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus","phase":"","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Hopital of Melun","has_results":false},{"nct_id":"NCT06344338","title":"Application of tDCS Stimulation in Controlling Refractory Status Epilepticus","phase":"NA","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05851391","title":"buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02052739","title":"Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05934903","title":"Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus","phase":"NA","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05684978","title":"Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Wayne State University","has_results":false},{"nct_id":"NCT02433314","title":"An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}